BridgeBio Oncology Therapeutics: COO & principal financial officer Elmelech Idan sold 343 shares

What happened The filing reports that Elmelech Idan, COO & principal financial officer, had 343 shares of common stock withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. The shares were withheld at $3.94 per share for a total value of $1,351 on Oct 1, 2026 (transaction code F).

Key details

• Transaction date and price: Oct 1, 2026 — 343 shares withheld at $3.94 per share; total $1,351.
• Filing date: Oct 5, 2026. The filing does not indicate it was filed late.
• Shares owned after the transaction: the filing does not report the number of shares owned following the transaction.
• Footnote: F1 — represents the number of shares withheld by the issuer to satisfy the reporting person’s tax withholding obligations in connection with the vesting of restricted stock units.
• Transaction code: F (tax withholding).

Why it may matter

• This was a tax withholding related to restricted stock unit vesting, not an open-market sale.
• This filing does not show why the insider traded or why the company acted.